📰 Beigene News
Page 17 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
May 16, 2022
Equities research analysts expect BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) to report sales of $332.26 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for BeiGene’s earnings, with the highest sales estimate coming in at $347.62 million and the lowest estimate coming in at $316.90 million. BeiGene reported […]
May 12, 2022
Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy
May 11, 2022
BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]
May 5, 2022
Recorded product revenue of $261.6 million for the first quarter, representing a 146% increase from $106.1 million in the prior year period BRUKINSA product revenue increased 372% globally
May 4, 2022
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for
May 2, 2022
BeiGene (NASDAQ:BGNE – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $179.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 7.49% […]
April 29, 2022
Flagship U.S. Facility Will Include Biologic Manufacturing and Late Stage Research and Clinical Development of Innovative Cancer Medicines Sixth U.S. Location Adds to Global Expansion and Brings
April 29, 2022
Astellas takes gene therapy hit. Novartis and BeiGene post PD-1 win. Serum Institute halts COVID vaccine production.
April 27, 2022
27.04.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the ... Seite 1
April 27, 2022
Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3